FDA clearance is a critical regulatory milestone that often leads to increased adoption and sales of medical devices. This clearance expands the TEG 6s system's applications to critical areas such as cardiovascular surgeries and liver transplants, potentially leading to increased demand and revenue for Haemonetics. Given the specificity of the clearance and its importance in expanding the device's use cases, this news is likely to be viewed positively by investors, potentially leading to a short-term uptick in Haemonetics' stock price.